Unique ID issued by UMIN | UMIN000029262 |
---|---|
Receipt number | R000033447 |
Scientific Title | Examination of virological response and predictive factors in Elbasvir/Grazoprevir combination therapy for genotype1 infected chronic hepatitis C patients |
Date of disclosure of the study information | 2017/09/25 |
Last modified on | 2021/06/23 06:17:13 |
Examination of virological response and predictive factors in Elbasvir/Grazoprevir combination therapy for genotype1 infected chronic hepatitis C patients
Examination of virological response and predictive factors in Elbasvir/Grazoprevir combination therapy
Examination of virological response and predictive factors in Elbasvir/Grazoprevir combination therapy for genotype1 infected chronic hepatitis C patients
Examination of virological response and predictive factors in Elbasvir/Grazoprevir combination therapy
Japan |
Chronic hepatitis C
Gastroenterology |
Others
NO
To confirm the predictive factors associated with virological response and efficacy in Elbasvir/Grazoprevir combination therapy for genotype1 infected chronic hepatitis C patients.
Safety,Efficacy
Sustained virological response 12 rate
1. Change in serum HCV RNA during treatment and follow-up duration
2. Change in hematological and biochemical test during treatment and follow-up duration
3. Change in Mac-2 Binding Protein,hyaluronic acid, type IV collagen,gamma globulin during treatment and follow-up duration.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Treat with Elbasvir/Grazoprevir combination therapy
ERELSA 50mg:one tablet once a day for 12 weeks
GRAZYNA 50mg:two tablets once a day for 12 weeks
18 | years-old | <= |
85 | years-old | > |
Male and Female
Patients who treated with Elbasvir/Grazoprevir combination therapy.
Patients with chronic hepatits C, genotype 1
1.History of allergy to Elbasvir/Grazoprevir
2.Decompensated liver cirrhosis
3.pregnant woman or lactating mother
4.Hepatocellular carcinoma, or other malignant tumor.
5.severe depression
6.Judged by investigator not to be appropriate for inclusion in this study
7.Receiving contraindicated drugs for
Elbasvir/Grazoprevir combined therapy
300
1st name | Tomomi |
Middle name | |
Last name | Okubo |
Nippon Medical School Chiba Hokusoh Hospital
Division of Gastroenterology
270-1196
1715,Kamakari,Inzai,Chiba, 270-1694, Japan
0476991111
atsukawa-nms@umin.ac.jp
1st name | Tomomi |
Middle name | |
Last name | Okubo |
Nippon Medical School Chiba Hokusoh Hospital
Division of Gastroenterology
270-1196
1715,Kamakari,Inzai,Chiba, 270-1694, Japan
0476991111
ma6-0154@nms.ac.jp
Nippon Medical School Chiba Hokusoh Hospital
None
Self funding
Nippon Medical School Hospital
Nippon Medical School Musashi Kosugi Hospital
The Jikei University Hospital
Otakanomori Hospital
Hakujikai Healthcare foundation
Tokyo Metropolitan Bokutoh Hospital
Tokyo Medical University Ibaraki Medical Center
Shinmatsudo Central General Hospital
Japanese Red Cross Narita Hospital
Nagoya City University Hospital
Nipon medical Chiba hokuso Hospital
1715 Kamagari Inzai Chiba
0476991111
araraki@nms.ac.jp
NO
2017 | Year | 09 | Month | 25 | Day |
Unpublished
Main results already published
2017 | Year | 06 | Month | 21 | Day |
2017 | Year | 06 | Month | 05 | Day |
2017 | Year | 07 | Month | 05 | Day |
2021 | Year | 03 | Month | 30 | Day |
2017 | Year | 09 | Month | 24 | Day |
2021 | Year | 06 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033447